منابع مشابه
Targeting HER2: precision oncology for colorectal cancer.
www.thelancet.com/oncology Vol 17 June 2016 685 Advanced colorectal cancer still has a poor prognosis and more active drugs are urgently needed. HER2 was investi gated as a target in colorectal cancer in two early trials of trastuzumab plus chemotherapy as fi rst, second or third line therapy, which produced interesting but confl icting results. In The Lancet Oncology, Andrea Sartore-Bianchi an...
متن کاملDual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
PURPOSE Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer that commonly harbors HER2 gene amplification. We investigated the effectiveness of HER2 inhibition using lapatinib and trastuzumab in vitro and in xenografts derived from USC cell lines and USC patient-derived xenografts. EXPERIMENTAL DESIGN Immunohistochemistry and FISH were performed to assess HER2 expres...
متن کاملMultiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
Multi-targeting strategies improve the efficacy of antibody and immunotoxin therapies but have not yet been thoroughly explored for HER2-based cancer treatments. We investigated multi-epitope HER2 targeting to boost photosensitizer immunoconjugate uptake as a way of enhancing photoimmunotherapy. Photoimmunotherapy may allow targeted photodynamic destruction of malignancies and may also potentia...
متن کاملSynergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Amplification of human epidermal growth factor receptor 2 (HER2) has been detected in 20% to 30% of gastric cancers and is associated with a poor outcome. Combination therapies with HER2-targeting agents and cytotoxic agents are considered a potential therapeutic option for gastric cancer with HER2 amplification. We have now investigated the effects of combination treatment with the oral fluoro...
متن کاملCombined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Brain metastases are a serious obstacle in the treatment of patients with human epidermal growth factor receptor-2 (HER2)-amplified breast cancer. Although extracranial disease is controlled with HER2 inhibitors in the majority of patients, brain metastases often develop. Because these brain metastases do not respond to therapy, they are frequently the reason for treatment failure. We developed...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: mAbs
سال: 2010
ISSN: 1942-0862,1942-0870
DOI: 10.4161/mabs.2.5.13054